In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …

Abstract The American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012
survey of meeting attendees showed that existing ASRA anticoagulation guidelines for …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Interventional spine and pain procedures cover a far broader spectrum than those for
regional anesthesia, reflecting diverse targets and goals. When surveyed, interventional …

Background—The increasing use of higher-than-approved doses of clopidogrel in clinical
practice is based in part on the desire for greater levels of inhibition of platelet aggregation …

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute
myocardial infarction. Recent advances in understanding the molecular basis of the role of …

Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine‐
5′‐diphosphate (ADP)‐mediated platelet aggregation in vivo. These compounds are …

Currently, clopidogrel is recommended for treatment of patients with acute coronary
syndrome and/or percutaneous coronary intervention. However, the delayed onset of the …

Aims P2Y 12 receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were
investigated in patients with stable coronary artery disease. Methods and results One …

Objectives: We evaluated the relative contributions of the loading and maintenance doses of
prasugrel on events in a TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic …